Rurioctocog alfa pegol - Takeda
Alternative Names: Adynovate; Adynovi; BAX-855; EHL rFVIII PEG; Extended half-life recombinant FVIII; Full-length longer-acting rFVIII; LA rFVIII PEG; PEG factor VIII; PEGylated recombinant factor VIII; PEGylated rFVIII; SHP-660; TAK 660Latest Information Update: 09 Oct 2024
At a glance
- Originator Baxter International; Nektar Therapeutics
- Developer Baxter International; Nektar Therapeutics; Takeda
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Factor VIII replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemophilia A
Most Recent Events
- 05 Sep 2024 Takeda completes a phase III trial for Haemophilia A (In children, In adolescents, In adults, Treatment-experienced, Prevention) in China (IV) (NCT05707351)
- 27 Mar 2023 Phase-III clinical trials in Haemophilia A (In adolescents, In adults, Prevention, Treatment-experienced) in China (IV) (NCT05707351)
- 27 Mar 2023 Phase-III clinical trials in Haemophilia A (In adolescents, In adults, Treatment-experienced) in China (IV) (NCT05707351)